Responses
Correction
Correction: Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial
Compose a Response to This Article
Other responses
No responses have been published for this article.
